Thomas Oellerich

Goethe University Frankfurt
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

Year:

2025

Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

Year:

2025

Supplementary Figure S1 shows enrichment of FBL in LSC, correlation of FBL with LSC signature and rRNA 2'-O-Me in healthy hematopoietic cells. Supplementary Figure S2 shows the association of rRNA 2’-O-Me with LSC and hematopoietic differentiation signatures. Supplementary Figure S3 shows strategy for LSC sorting and distribution of LSC methylation sites on ribosomes. Supplementary Figure S4 shows the effect of FBL knockdown on rRNA 2’-O-methylation and in vitro proliferation of leukemia cells. Supplementary Figure S5 show the effect of FBL overexpression on in vivo engraftment of primary AML cells. Supplementary Figure S6 shows the effect of FBL knockdown on nascent proteome and metabolism of AML cells. Supplementary Figure S7 shows the ribosome footprinting analysis after FBL knockdown. Supplementary Figure S8 shows the association of Gm1447 with LSC signature and the effect of Gm1447 supression on cellular amino acid levels. Supplementary Figure S9 shows regulatory effect of Gm1447 on in vivo leukemic self-renewal.

Year:

2025

Supplementary table S1 shows all rRNA 2’-O-methylation sites identified in human AMLs. Supplementary table S2 shows dynamic rRNA 2’-O-methylation sites in each DyMeC cluster. Supplementary table S3 shows the location of rRNA 2’-O-methylation static sites in ribosome regions. Supplementary table S4 shows proteins with altered translation after FBL knockdown.

Year:

2025

Diffuse large B-cell lymphoma (DLBCL) can be subdivided into the activated B-cell (ABC) and germinal center B cell–like (GCB) subtypes. Self-antigen engagement of B-cell receptors (BCR) in ABC tumors induces their clustering, thereby initiating chronic active signaling and activation of NF-κB and PI3 kinase. Constitutive BCR signaling is essential in some GCB tumors but primarily activates PI3 kinase. We devised genome-wide CRISPR–Cas9 screens to identify regulators of IRF4, a direct transcriptional target of NF-κB and an indicator of proximal BCR signaling in ABC DLBCL. Unexpectedly, inactivation of N-linked protein glycosylation by the oligosaccharyltransferase-B (OST-B) complex reduced IRF4 expression. OST-B inhibition of BCR glycosylation reduced BCR clustering and internalization while promoting its association with CD22, which attenuated PI3 kinase and NF-κB activation. By directly interfering with proximal BCR signaling, OST-B inactivation killed models of ABC and GCB DLBCL, supporting the development of selective OST-B inhibitors for the treatment of these aggressive cancers. Significance: DLBCL depends on constitutive BCR activation and signaling. There are currently no therapeutics that target the BCR directly and attenuate its pathologic signaling. Here, we unraveled a therapeutically exploitable, OST-B–dependent glycosylation pathway that drives BCR organization and proximal BCR signaling. This article is highlighted in the In This Issue feature, p. 1749

Year:

2025

The development and regulation of malignant self-renewal remain unresolved issues. Here, we provide biochemical, genetic, and functional evidence that dynamics in ribosomal RNA (rRNA) 2′-O-methylation regulate leukemia stem cell (LSC) activity in vivo . A comprehensive analysis of the rRNA 2′-O-methylation landscape of 94 patients with acute myeloid leukemia (AML) revealed dynamic 2′-O-methylation specifically at exterior sites of ribosomes. The rRNA 2′-O-methylation pattern is closely associated with AML development stage and LSC gene expression signature. Forced expression of the 2′-O-methyltransferase fibrillarin (FBL) induced an AML stem cell phenotype and enabled engraftment of non-LSC leukemia cells in NSG mice. Enhanced 2′-O-methylation redirected the ribosome translation program toward amino acid transporter mRNAs enriched in optimal codons and subsequently increased intracellular amino acid levels. Methylation at the single site 18S-guanosine 1447 was instrumental for LSC activity. Collectively, our work demonstrates that dynamic 2′-O-methylation at specific sites on rRNAs shifts translational preferences and controls AML LSC self-renewal. Significance: We establish the complete rRNA 2′-O-methylation landscape in human AML. Plasticity of rRNA 2′-O-methylation shifts protein translation toward an LSC phenotype. This dynamic process constitutes a novel concept of how cancers reprogram cell fate and function. This article is highlighted in the In This Issue feature, p. 247

Year:

2025

Tissue-specific differences in the expression of paralog genes, which are not essential in most cell types due to the buffering effect of the partner pair, can make for highly selective gene dependencies. To identify selective paralogous targets for acute myeloid leukemia (AML), we integrated the Cancer Dependency Map with numerous datasets characterizing protein–protein interactions, paralog relationships, and gene expression in cancer models. In this study, we identified ATP1B3 as a context-specific, paralog-related dependency in AML. ATP1B3, the β-subunit of the sodium–potassium pump (Na/K-ATP pump), interacts with the α-subunit ATP1A1 to form an essential complex for maintaining cellular homeostasis and membrane potential in all eukaryotic cells. When ATP1B3’s paralog ATP1B1 is poorly expressed, elimination of ATP1B3 leads to the destabilization of the Na/K-ATP pump. ATP1B1 expression is regulated through epigenetic silencing in hematopoietic lineage cells through histone and DNA methylation in the promoter region. Loss of ATP1B3 in AML cells induced cell death in vitro and reduced leukemia burden in vivo , which could be rescued by stabilizing ATP1A1 through overexpression of ATP1B1 . Thus, ATP1B3 is a potential therapeutic target for AML and other hematologic malignancies with low expression of ATP1B1 . Significance: ATP1B3 is a lethal selective paralog dependency in acute myeloid leukemia that can be eliminated to destabilize the sodium–potassium pump, inducing cell death.

Year:

2024

Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

Year:

2024

Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

Year:

2024

Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (19)

Daria Fijałkowska

Staff scientists: data analyst

Vlaams Instituut voor Biotechnologie

BELGIUM
View details

Haiyang Yun

Group Leader

Heidelberg University

GERMANY
View details

Jiji Chen

National Institutes of Health

UNITED STATES
View details

Tim Sauer

Heidelberg University

GERMANY
View details

Caroline Pabst

Heidelberg University

GERMANY
View details

Hubert Serve

Klinikdirektor, Professor

Goethe University Frankfurt

GERMANY
View details

Yanlong Ji

Research Lab Specialist Senior

University of Michigan

UNITED STATES
View details

Clive DSantos

Head of Proteomics

University of Cambridge

UNITED KINGDOM
View details

Daniel James Hodson

-

UNITED KINGDOM
View details

Jeroen Krijgsveld

Deutsches Krebsforschungszentrum

GERMANY
View details

Lucy Merickel

Dana-Farber Cancer Institute

UNITED STATES
View details

Jae Woo Choi

Yonsei University Health System

SOUTH KOREA
View details

Michaela Frye

Professor

Deutsches Krebsforschungszentrum

GERMANY
View details

George Wright

National Institutes of Health

UNITED STATES
View details

Henning Urlaub

Professor

Max Planck Institute for Multidisciplinary Sciences

GERMANY
View details

Fengbiao Zhou

Group leader

Heidelberg University

GERMANY
View details

Carsten Müller-Tidow

Medical Director

University Hospital Heidelberg

GERMANY
View details

James Phelan

National Cancer Institute

UNITED STATES
View details

Kimberly Stegmaier

Chair, Department of Pediatric Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details